Titlebook: Resistance of Cancer Cells to CTL-Mediated Immunotherapy; Benjamin Bonavida,Salem Chouaib Book 2015 Springer International Publishing Swit

神圣將軍

樹木中

裂縫

GIST

Overcoming Cancer Cell Resistance to Death Receptor Targeted Therapiesn understanding the molecular mechanisms involved in cancer cell resistance to DR4/DR5 targeted therapies. This information will be further discussed with respect to combinational strategies to overcome or bypass resistance mechanisms towards a better treatment outcome.

pacific

取回

Charitable

薄膜

Role of the Non-classical HLA Class I Antigens for Immune Escape non-classical HLA-G antigen is often overexpressed in solid and hematopoietic tumors, thereby, creating a tolerogenic phenotype leading to an escape from T and NK cell-mediated immune responses by binding to the inhibitory receptors ILT2, ILT4 and KIR2DL4. Consequently, HLA-G. tumors are associated

Hyperlipidemia

Integrins: Friends or Foes of Antitumor Cytotoxic T Lymphocyte Responseotherapy approaches aim at generating tumor-specific CTL capable of migrating to the tumor site and at optimizing their functional activities toward target cells. Unfortunately, clinical trials indicate that despite an increase in the frequency and reactivity of antitumor CD8. T lymphocytes, the eff

我不死扛

Cytotoxic T Lymphocytes and Their Granzymes: An Overviewed on these findings, a number of cancer immunotherapies have been designed, each utilising a different approach to acquire their lethal skills. However, despite the sound rationale underlying CTL-based immunotherapies, treatment resistance remains a galling obstacle. This review provides an overvie